Trial Profile
ONCOSUR AVALOX Study: Identification of Potential Factors with the Selection of First-line Bevacizumab+Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms ONCOSUR AVALOX
- 11 Dec 2015 New trial record
- 01 Dec 2015 Results published in the Anticancer Research